Innovative and orphan drugs to become more accessible in Russia

30 September 2014

The Russian Parliament (State Duma) plans to ease access to innovative and orphan drugs to the Russian market through the introduction of amendments to the existing federal law “On Circulation of Drugs” in Russia.

Officials believe that this is an urgent need, as pharmaceutical manufacturers have long been complaining about the length and complexity of the procedures for registration of new drugs in Russia, which is currently 210 working days and which, according to drugmakers, slows down their appearance in local pharmacies and hospitals.

Until now, the government did not have any plans to introduce any changes in the existing procedure. However, there is a possibility that the current registration scheme might be changed in the case of innovative and orphan drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK